Page 234 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 234
Chapter 8
Overall Survival
Supplemental Table 10. HRs for DS4-5, DS5 and ∆SUVmax PET response criteria with 2-year OS as outcome.
Timing DS1-3 vs 4-5
HR (95% CI)
1 0.95 (0.35-2.57)
2 1.81 (1.31-2.50)
3 3.18 (0.93-10.90)
4 3.68 (2.29-5.89)
Abbreviations are explained in Table 1.
DS1-4 vs 5
HR (95% CI) 1.88 (0.66-5.36) 5.52 (3.72-8.19) 7.20 (1.90-27.24) 7.62 (4.34-13.37)
∆SUVmax
HR (95% CI) 1.11 (0.31-3.92) 3.70 (2.62-5.21) 3.53 (0.91-13.66) 5.11 (2.84-9.19)
Supplemental Table 11. PPV and NPV for DS4-5, DS5 and ∆SUVmax PET response criteria at I-PET2 and I-PET4 with 2-year OS as outcome.
I-PET criteria
I-PET2 DS1-3 vs 4-5 DS1-4 vs 5
∆SUVmax I-PET4 DS1-3 vs 4-5
DS1-4 vs 5 ∆SUVmax
Abbreviations are explained in Table 2.
PPV (95% CI)
20.6 (16.8-24.4) 53.6 (40.9-66.3) 35.5 (27.5-43.6) 34.2 (24.9-43.4) 60.7 (41.2-80.2) 45.2 (29.0-61.5)
NPV (95% CI)
89.6 (87.3-92.0) 87.8 (85.7-89.8) 88.3 (86.3-90.4) 90.7 (87.8-93.6) 88.1 (85.1-91.1) 88.2 (84.7-91.8)
and between positive I-PET timings
Supplemental Table 12. HRs between negative I-PET timings compared to I-PET2 with 2-year OS as outcome.
I-PET1 negative I-PET2 negative I-PET3 negative I-PET4 negative I-PET1 positive I-PET2 positive I-PET3 positive I-PET4 positive
DS1-3 vs 4-5 (95% CI)
2.18 (0.94-5.06) 1 (reference) 1.18 (0.54-2.58) 0.69 (0.45-1.04) 1.15 (0.61-2.15) 1 (reference) 2.07 (0.76-5.66) 1.39 (0.94-2.07)
DS1-4 vs 5 (95% CI)
1.63 (0.90-2.96) 1 (reference) 1.09 (0.53-2.23) 0.77 (0.56-1.07) 0.56 (0.22-1.43) 1 (reference) 1.42 (0.43-4.65) 1.07 (0.58-1.96)
∆SUVmax (95% CI)
1.88 (0.83-4.29) 1 (reference) 1.18 (0.55-2.54) 0.78 (0.54-1.14) 0.56 (0.20-1.57) 1 (reference) 1.13 (0.35-3.63) 1.08 (0.61-1.91)
Abbreviations are explained in Supplemental Table 5.
232
